Chronic kidney disease: global dimension and perspectives.
Lancet. 2013; 382: 260-272
Rev Med Chil. 2011; 139: 1176-1184
KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
Kidney Int Suppl. 2013; 3: 1-150
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention.
Lancet. 2013; 382: 339-352
Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality.
JAMA. 2014; 311: 2518-2531
Estimated glomerular filtration rate, urine albumin excretion, and survival among patients consulting in public Chilean public primary care clinics.
Ren Fail. 2016; 38: 397-403
Early recognition and prevention of chronic kidney disease.
Lancet. 2010; 375: 1296-1309
Effects of polyunsaturated fatty acid consumption in diabetic nephropathy.
Nat Rev Nephrol. 2011; 7: 110-121
Inducible NOS inhibition, eicosapentaenoic acid supplementation, and angiotensin II-induced renal damage.
Kidney Int. 2005; 67: 248-258
Cross-sectional association between fish consumption and albuminuria: the European Prospective Investigation of Cancer-Norfolk Study.
Am J Kidney Dis. 2008; 52: 876-886
Polyunsaturated fatty acid consumption may play a role in the onset and regression of microalbuminuria in well-controlled type 1 and type 2 diabetic people: a 7-year, prospective, population-based, observational multicenter study.
Diabetes Care. 2004; 27: 1454-1457
Eicosapentaenoic and docosahexaenoic acids attenuate progression of albuminuria in patients with type 2 diabetes mellitus and coronary artery disease.
J Am Heart Assoc. 2017; 6: e004740
Partial normalization by dietary cod-liver oil of increased microvascular albumin leakage in patients with insulin-dependent diabetes and albuminuria.
N Engl J Med. 1989; 321: 1572-1577
Fish oil in diabetic nephropathy.
Diabetes Care. 1996; 19: 1214-1219
Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study.
Clin Nephrol. 1994; 41: 183-190
The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group.
J Am Soc Nephrol. 1999; 10: 1772-1777
US family physicians overestimate personal Ω-3 fatty acid biomarker status: associations with fatty fish and Ω-3 supplement intake.
Curr Dev Nutr. 2017; 2: nzx007
Biological variability of estimated GFR and albuminuria in CKD.
Am J Kidney Dis. 2018; 72: 538-546
Higher plasma phospholipid n-3 PUFAs, but lower n-6 PUFAs, are associated with lower pulse wave velocity among older adults.
J Nutr. 2015; 145: 2317-2324
Arterial stiffness in chronic kidney disease: a modifiable cardiovascular risk factor?.
Curr Opin Nephrol Hypertens. 2019; 28: 527-536
Inflammation and arterial stiffness in chronic kidney disease: cause or consequence?.
Am J Hypertens. 2017; 30: 350-352
Association of the triglycerides to high-density lipoprotein cholesterol ratio with the risk of chronic kidney disease: analysis in a large Japanese population.
Atherosclerosis. 2014; 233: 260-267
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
Circulation. 2013; 128: e240-e327
A rapid method of total lipid extraction and purification.
Can J Biochem Physiol. 1959; 37: 911-917
Omega-3 fatty acids in cardiac biopsies from heart transplantation patients: correlation with erythrocytes and response to supplementation.
Circulation. 2004; 110: 1645-1649
Pulse wave analysis using the Mobil-O-Graph, Arteriograph and Complior device: a comparative study.
Blood Press. 2019; 28: 107-113
Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: summary and discussion of the American Society of Echocardiography consensus statement.
Prev Cardiol. 2009; 12: 34-38
Analysis of repeated measurement data using the non linear mixed effects model.
Chemometrics Intell Lab Syst. 1993; 20: 1-24
Obesity-associated glomerular inflammation increases albuminuria without renal histological changes.
FEBS Open Bio. 2018; 8: 664-670
Omega-3 fatty acids, cardiovascular risk, and the resolution of inflammation.
FASEB J. 2019; 33: 1536-1539
The effect of n-3 long-chain polyunsaturated fatty acid supplementation on urine protein excretion and kidney function: meta-analysis of clinical trials.
Am J Clin Nutr. 2009; 89: 1937-1945
Effect of vitamin D and omega-3 fatty acid supplementation on kidney function in patients with type 2 diabetes: a randomized clinical trial.
JAMA. 2019; 322: 1899-1909
Arterial stiffness: a novel cardiovascular risk factor in kidney disease patients.
Curr Vasc Pharmacol. 2015; 13: 229-238
An increase in the EPA/AA ratio is associated with improved arterial stiffness in obese patients with dyslipidemia.
J Atheroscler Thromb. 2014; 21: 248-260
Omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect in adults with metabolic syndrome.
Atherosclerosis. 2014; 232: 10-16
Arterial stiffness in CKD: a review.
Am J Kidney Dis. 2019; 73: 240-247
Maximum home systolic blood pressure is a useful indicator of arterial stiffness in patients with type 2 diabetes mellitus: post hoc analysis of a cross-sectional multicenter study.
Diabetes Res Clin Pract. 2014; 105: 344-345
Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: a longitudinal study in a large Japanese population.
Am J Kidney Dis. 2015; 66: 972-983
Serum triglycerides and risk for death in Stage 3 and Stage 4 chronic kidney disease.
Nephrol Dial Transpl. 2012; 27: 3228-3234
Elevated plasma glucose and lowered triglyceride levels from omega-3 fatty acid supplementation in type II diabetes.
Diabetes Care. 1989; 12: 276-281
Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus.
Cochrane Database Syst Rev. 2008; : CD003205
Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.
N Engl J Med. 2019; 380: 11-22